SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 5, 2013
PROPHASE LABS, INC.
(Exact name of Company as specified in its charter)
Company's telephone number, including area code: (215) 345-0919
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
Matrixx Initiatives, Inc. informed ProPhase Labs, Inc. (the “Company”) on February 5, 2013 that it has withdrawn its unsolicited offer to acquire the Company. Ted Karkus, Chief Executive Officer of the Company, stated that “While the Company is gratified that a significant competitor had expressed an interest in acquiring the Company, we remain committed to our view that our long-term growth strategy to build shareholder value is in our shareholders’ best interests.”
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 6, 2013